The 56th Annual Meeting of the American Society of Hematology (ASH) will be held in San Francisco, CA from December 6-9, 2014. We have assembled a pre-meeting listing of highlights based on presentation titles and abstracts that were released.
Updated 11/26/2014: A full ASH meeting planner has been added to the 2014 BioMedTracker Pre-ASH Report.
This year's meeting features data on the promising CAR-T immunotherapies. Some PD-1 checkpoint immunotherapies, which have fared so well with solid tumors, will also have their first data released in hematologic cancers. The Bcl-2 inhibitor, ABT-199 (ABBV) will be heavily featured in presentations for AML, CLL, and NHL. The meeting will also feature data for more mature drugs like Kyprolis (carfilzomib), which should present updated data as the drug moves towards full approval. Outside of oncology, focus will be on the expanding hemophilia competition and the emergence of long-acting Factor VIII therapies.

For our disclosures, please read the BioMedTracker Research Standards.